CA3029889A1 - 4-anilino-quinoline compounds as anti-cancer agents - Google Patents
4-anilino-quinoline compounds as anti-cancer agents Download PDFInfo
- Publication number
- CA3029889A1 CA3029889A1 CA3029889A CA3029889A CA3029889A1 CA 3029889 A1 CA3029889 A1 CA 3029889A1 CA 3029889 A CA3029889 A CA 3029889A CA 3029889 A CA3029889 A CA 3029889A CA 3029889 A1 CA3029889 A1 CA 3029889A1
- Authority
- CA
- Canada
- Prior art keywords
- amine
- quinolin
- methoxyphenyl
- compound
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305862 | 2016-07-08 | ||
| EP16305862.1 | 2016-07-08 | ||
| PCT/EP2017/067306 WO2018007648A1 (en) | 2016-07-08 | 2017-07-10 | 4-anilino-quinoline compounds as anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3029889A1 true CA3029889A1 (en) | 2018-01-11 |
Family
ID=56413606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3029889A Pending CA3029889A1 (en) | 2016-07-08 | 2017-07-10 | 4-anilino-quinoline compounds as anti-cancer agents |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200181089A1 (enExample) |
| EP (1) | EP3481806B1 (enExample) |
| JP (1) | JP7039579B2 (enExample) |
| AU (1) | AU2017294572B2 (enExample) |
| CA (1) | CA3029889A1 (enExample) |
| WO (1) | WO2018007648A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019134975A1 (en) | 2018-01-05 | 2019-07-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Substituted halo-quinoline derivatives, method of preparation and applications thereof |
| CN113549018B (zh) * | 2020-04-24 | 2024-02-27 | 中国药科大学 | 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用 |
| EP4169904A1 (en) | 2021-10-25 | 2023-04-26 | Yukin Therapeutics | Substituted quinolines as improved nf-kb-inducing kinase (nik) inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075981A (en) * | 1958-04-03 | 1963-01-29 | Sterling Drug Inc | 1-[aromatic-(lower-alkyl)]-4-(aromaticimino)-1, 4-dihydroquinolines and their preparation |
| BE640616A (enExample) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| WO2008089307A2 (en) * | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
| CN102249997A (zh) | 2011-05-25 | 2011-11-23 | 沈阳化工大学 | 一组具有抗肿瘤活性的4-取代苯氨基喹啉化合物 |
| US10322125B2 (en) | 2013-02-22 | 2019-06-18 | Emory University | TGF-beta enhancing compositions for cartilage repair and methods related thereto |
| CN103232444B (zh) | 2013-04-18 | 2015-07-22 | 中国人民解放军军事医学科学院微生物流行病研究所 | 萘酚喹衍生物及其制备和其应用 |
-
2017
- 2017-07-10 US US16/315,930 patent/US20200181089A1/en not_active Abandoned
- 2017-07-10 JP JP2019521185A patent/JP7039579B2/ja active Active
- 2017-07-10 WO PCT/EP2017/067306 patent/WO2018007648A1/en not_active Ceased
- 2017-07-10 EP EP17735589.8A patent/EP3481806B1/en active Active
- 2017-07-10 AU AU2017294572A patent/AU2017294572B2/en active Active
- 2017-07-10 CA CA3029889A patent/CA3029889A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017294572B2 (en) | 2021-11-04 |
| US20200181089A1 (en) | 2020-06-11 |
| AU2017294572A2 (en) | 2019-05-09 |
| AU2017294572A1 (en) | 2019-01-24 |
| EP3481806C0 (en) | 2023-06-07 |
| EP3481806A1 (en) | 2019-05-15 |
| JP7039579B2 (ja) | 2022-03-22 |
| EP3481806B1 (en) | 2023-06-07 |
| JP2019521193A (ja) | 2019-07-25 |
| WO2018007648A1 (en) | 2018-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522293A (ja) | ナトリウムチャネルのモジュレーターとしての置換テトラヒドロフラン類似体 | |
| CA2889389C (en) | Benzene sulfonamide thiazole compounds | |
| JP2019055974A (ja) | ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ | |
| CA2922753C (en) | 1-(4-pyrimidinyl)-1h-pyrrolo[3,2-c]pyridine derivatives as nik inhibitors | |
| HK1204623A1 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
| US20210292340A1 (en) | Cell necrosis inhibitor, preparation method therefor and use thereof | |
| CN105722840B (zh) | 作为PI3K、mTOR抑制剂的稠合喹啉化合物 | |
| WO2012109423A1 (en) | Method of inhibiting hamartoma tumor cells | |
| KR102228034B1 (ko) | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 | |
| EP3481806B1 (en) | 4-anilino-quinoline compounds as anti-cancer agents | |
| KR20220091528A (ko) | 4-아미노-이미다조퀴놀린 화합물 및 이의 용도 | |
| AU2019205595B2 (en) | Substituted halo-quinoline derivatives, method of preparation and applications thereof | |
| KR20220068224A (ko) | Perk 억제 화합물 | |
| JP7152078B2 (ja) | ホウ酸塩ベースの薬物およびその使用 | |
| EP4034103A1 (en) | Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections | |
| HK1248227A1 (zh) | 酚噻嗪化合物及其用途 | |
| KR20140033643A (ko) | 야누스 키나아제 3을 활성을 선택적으로 저해하는 플라보노이드 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220711 |
|
| EEER | Examination request |
Effective date: 20220711 |
|
| EEER | Examination request |
Effective date: 20220711 |
|
| EEER | Examination request |
Effective date: 20220711 |
|
| EEER | Examination request |
Effective date: 20220711 |